A Cost-Utility Analysis Comparing Two Sequences of Treatment for First-Line Chemotherapy in Metastatic Prostate Cancer (MCRPC)- Cabazitaxel Followed by Docetaxel Versus Docetaxel Followed by Cabazitaxel
Abstract
Authors
M Schwager K Fizazi N Zaghdoud R Delva G Gravis Mescam G Baciarello C Theodore M Gross Goupil E Bompas F Joly Y Tazi T L'Haridon T N'guyen P Barthelemy S Culine J Berdah M Deblock P Beuzedoc A Flechon C Cheneau G Martineau I Borget